Publicaciones en colaboración con investigadores/as de Groupe Hospitalier Diaconesses Croix Saint-Simon (3)

2024

  1. Tisotumab Vedotin as Second- or Third-Line Therapy for Recurrent Cervical Cancer

    New England Journal of Medicine, Vol. 391, Núm. 1, pp. 44-55

2021

  1. Patient-centred outcomes and effect of disease progression on health status in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation receiving maintenance olaparib or placebo (SOLO1): a randomised, phase 3 trial

    The Lancet Oncology, Vol. 22, Núm. 5, pp. 632-642

2019

  1. Olaparib plus bevacizumab as first-line maintenance in ovarian cancer

    New England Journal of Medicine, Vol. 381, Núm. 25, pp. 2416-2428